| 25. P3. Variation in resting metabolic rate in MF1 mice is not associated with membrane lipid desaturation in the liver: a test of the ‘membrane pacemaker’hypothesis C Haggerty, N Hoggard, DS Brown, JC Clapham, JR Speakman Comparative Biochemistry and Physiology, Part A, S115, 2007 | | 2007 |
| 35th annual meeting of the European Association for the Study of diabetes: Brussels, Belgium, 28 September–2 October 1999 A Melander, J Olsson, G Lindberg, A Salzman, T Howard, P Stang, ... Diabetologia 42, A1-A330, 1999 | 9 | 1999 |
| A longitudinal magnetic resonance imaging (MRI) study of differences in abdominal fat distribution between normal mice, and lean overexpressors of mitochondrial uncoupling … KK Changani, A Nicholson, A White, JK Latcham, DG Reid, JC Clapham Diabetes, Obesity and Metabolism 5 (2), 99-105, 2003 | 33 | 2003 |
| A melanin-concentrating hormone receptor (SLC-1) antagonist reduces food intake and body weight gain in rats and mice AC Haynes, AJ Stevens, AI Muir, KY Avenell, JC Clapham, M Tadayyon, ... OBESITY RESEARCH 9, O152-O152, 2001 | | 2001 |
| A melanin-concentrating hormone receptor (SLC-1) antagonist reduces food intake and body weight gain in rats and mice AC Havnes, AJ Stevens, AI Muir, KY Avenell, JC Clapham, M Tadayyon, ... OBESITY RESEARCH 9, 90S-90S, 2001 | 2 | 2001 |
| A method for in vivo assessment of calcium slow channel blocking drugs JC Clapham Journal of cardiovascular pharmacology 11 (1), 56-60, 1988 | 5 | 1988 |
| A vasoactive substance with a molecular weight less than 3,000, released during hypoxic perfusion of isolated rat lungs, constricts isolated rat pulmonary, but not mesenteric … TP Robertson, JC Clapham, JPT Ward BRITISH JOURNAL OF PHARMACOLOGY 111, 277P-277P, 1994 | 4 | 1994 |
| Abnormalities of protein kinases in neurodegenerative diseases S Ren, EJ Lien, NC Turner, JC Clapham, L Prokai, RTE Wagey, C Krieger, ... Progress in drug research, 133-183, 1998 | 39 | 1998 |
| AMP-activated protein kinase is up-regulated in the brown adipose tissue of mice with high resting metabolic rate C Haggerty, JC Clapham, B Basta, N Hoggard, JR Speakman International Journal of Obesity 28, S83, 2004 | | 2004 |
| Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice AC Haynes, H Chapman, C Taylor, GBT Moore, MA Cawthorne, ... Regulatory peptides 104 (1-3), 153-159, 2002 | 193 | 2002 |
| Anti-obesity drugs: a critical review of current therapies and future opportunities JC Clapham, JRS Arch, M Tadayyon Pharmacology & therapeutics 89 (1), 81-121, 2001 | 155 | 2001 |
| Anti-spasmogenic and spasmolytic effects of BRL 34915: a comparison with nifedipine and nicorandil. JC Clapham, C Wilson Journal of Autonomic Pharmacology 7 (3), 233-242, 1987 | 42* | 1987 |
| Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models. JC Clapham, TC Hamilton, SD Longman, RE Buckingham, CA Campbell, ... Arzneimittel-forschung 41 (4), 385-391, 1991 | 45 | 1991 |
| Artefactual uncoupling following uncoupling protein 3 (UCP3) expression in yeast mitochondria JA Harper, JA Stuart, KM Brindle, MB Jekabsons, S Cadenas, ... BIOCHEMICAL SOCIETY TRANSACTIONS 29 (5), 120-120, 2001 | | 2001 |
| Assessment of the smooth muscle relaxant activity of the major human urinary metabolites of levcromakalim (BRL38227) JC Clapham, RE Buckingham, F Hicks, BK Trail, TC Hamilton Br J Pharmacol 108, 219P, 1993 | 3 | 1993 |
| Binding properties of antagonists to cannabinoid receptors in intact cells M Wennerberg, L Cheng, S Hjorth, JC Clapham, A Balendran, ... Fundamental & clinical pharmacology 25 (2), 200-210, 2011 | 17 | 2011 |
| Biomimicry as a basis for drug discovery S Ren, EJ Lien, NC Turner, JC Clapham, L Prokai, RTE Wagey, C Krieger, ... Progress in drug research, 185-217, 1998 | 19 | 1998 |
| BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. RE Buckingham, JC Clapham, TC Hamilton, SD Longman, J Norton, ... Journal of cardiovascular pharmacology 8 (4), 798-804, 1986 | 133 | 1986 |
| BRL-49653 PROTECTS AGAINST NEPHROPATHY IN OBESE ZUCKER RATS-FUNCTIONAL EVIDENCE K ALBARAZANJI, R Buckingham, N Turner, J CLAPHAM, M Slaughter Diabetes 44, A71-A71, 1995 | 3 | 1995 |
| Cell based in vitro and ex vivo models in metabolic disease drug discovery: nice to have or critical path? S Hallén, JC Clapham Expert Opinion on Drug Discovery 4 (4), 417-428, 2009 | 2 | 2009 |
